This Daptacel market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to public health initiatives and immunization programs, heightened awareness of preventable diseases, regulatory approvals and recommendations, the expansion of healthcare infrastructure, and government subsidies and funding.
Growth during the market's forecast period can be attributed to greater awareness of vaccine-preventable diseases, increased government support and policy changes, a stronger focus on preventative healthcare, growing demand for travel-related vaccinations, and an enhanced focus on pediatric immunization. Key trends expected in this period include advancements in vaccine technology and immunization systems, innovations in delivery methods, the development of rapid diagnostic tests, and the evolution of advanced vaccine monitoring technologies.
The growing prevalence of infectious diseases is expected to drive the expansion of the Daptacel market. Infectious diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread through various means, including person-to-person contact, vectors such as insects, contaminated surfaces or food, air, bodily fluids, or direct interaction with an infected individual. Factors such as globalization, climate change, antibiotic resistance, poor sanitation, and gaps in vaccination coverage contribute to the rapid spread and emergence of new pathogens. Daptacel, a vaccine for diphtheria, tetanus, and pertussis, helps reduce the prevalence of these diseases by providing immune protection in individuals. Widespread vaccination significantly reduces the occurrence of these diseases in communities. For example, in August 2024, the UK Health Security Agency reported 328 confirmed cases of diphtheria in 2023, involving 278 individuals (170 humans and 108 animals) in England, compared to 253 cases in 2022. Therefore, the rising prevalence of infectious diseases is driving the growth of the Daptacel market.
The growth of the Daptacel market is also expected to be driven by the increasing levels of travel and mobility. Improvements in transportation and the globalization of trade and business have made international travel more accessible and frequent. Additionally, the growth of tourism, cultural exchange, and enhanced connectivity has further boosted global mobility. Daptacel is crucial for travelers, offering protection against diphtheria, tetanus, and pertussis, thus reducing the risk of disease transmission across borders. For instance, Eurostat reported in October 2024 that in 2023, the EU saw nearly 2.9 billion nights spent in accommodations, with 1.6 billion of those nights spent by international visitors, compared to 2.8 billion in 2022. Notably, 15.6% of the nights spent by international guests in Europe were from tourists from regions outside Europe, an increase from 12.6% in 2022. This growing level of global travel and mobility is contributing to the expansion of the Daptacel market.
In November 2024, Amundi SA, a French asset management company, acquired a significant stake in Sanofi SA, a global pharmaceutical company that develops and markets medicines and vaccines, including Daptacel. With this acquisition, Amundi aims to strengthen its leadership in asset management and pursue responsible investment strategies.
The key player in the daptacel market is Sanofi S.A.
North America was the largest region in the daptacel market in 2024. The regions covered in daptacel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the daptacel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Daptacel is a DTaP vaccine that provides protection against diphtheria, tetanus, and pertussis (whooping cough) for children under 7 years old. It is part of the routine immunization schedule for children aged 6 weeks to 6 years, aiming to prevent potentially severe bacterial infections.
The primary technology types used in Daptacel include conjugate, live, recombinant, inactivated, and toxic vaccines. Conjugate vaccines are created by attaching a weak antigen to a stronger antigen, which helps enhance the immune system’s response to the weaker antigen. Daptacel conjugate vaccines are frequently utilized to boost immunity in children against various diseases. The vaccine is indicated for diphtheria, pertussis, and tetanus, and is used for both pediatric and adult age groups. Distribution channels for Daptacel include hospital pharmacies, retail pharmacies, and online pharmacies, with end users primarily consisting of hospitals and clinics.
The daptacel market research report is one of a series of new reports that provides daptacel market statistics, including daptacel industry global market size, regional shares, competitors with a daptacel market share, detailed daptacel market segments, market trends and opportunities, and any further data you may need to thrive in the daptacel industry. This daptacel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The daptacel market consists of sales of single-dose vials and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to public health initiatives and immunization programs, heightened awareness of preventable diseases, regulatory approvals and recommendations, the expansion of healthcare infrastructure, and government subsidies and funding.
Growth during the market's forecast period can be attributed to greater awareness of vaccine-preventable diseases, increased government support and policy changes, a stronger focus on preventative healthcare, growing demand for travel-related vaccinations, and an enhanced focus on pediatric immunization. Key trends expected in this period include advancements in vaccine technology and immunization systems, innovations in delivery methods, the development of rapid diagnostic tests, and the evolution of advanced vaccine monitoring technologies.
The growing prevalence of infectious diseases is expected to drive the expansion of the Daptacel market. Infectious diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread through various means, including person-to-person contact, vectors such as insects, contaminated surfaces or food, air, bodily fluids, or direct interaction with an infected individual. Factors such as globalization, climate change, antibiotic resistance, poor sanitation, and gaps in vaccination coverage contribute to the rapid spread and emergence of new pathogens. Daptacel, a vaccine for diphtheria, tetanus, and pertussis, helps reduce the prevalence of these diseases by providing immune protection in individuals. Widespread vaccination significantly reduces the occurrence of these diseases in communities. For example, in August 2024, the UK Health Security Agency reported 328 confirmed cases of diphtheria in 2023, involving 278 individuals (170 humans and 108 animals) in England, compared to 253 cases in 2022. Therefore, the rising prevalence of infectious diseases is driving the growth of the Daptacel market.
The growth of the Daptacel market is also expected to be driven by the increasing levels of travel and mobility. Improvements in transportation and the globalization of trade and business have made international travel more accessible and frequent. Additionally, the growth of tourism, cultural exchange, and enhanced connectivity has further boosted global mobility. Daptacel is crucial for travelers, offering protection against diphtheria, tetanus, and pertussis, thus reducing the risk of disease transmission across borders. For instance, Eurostat reported in October 2024 that in 2023, the EU saw nearly 2.9 billion nights spent in accommodations, with 1.6 billion of those nights spent by international visitors, compared to 2.8 billion in 2022. Notably, 15.6% of the nights spent by international guests in Europe were from tourists from regions outside Europe, an increase from 12.6% in 2022. This growing level of global travel and mobility is contributing to the expansion of the Daptacel market.
In November 2024, Amundi SA, a French asset management company, acquired a significant stake in Sanofi SA, a global pharmaceutical company that develops and markets medicines and vaccines, including Daptacel. With this acquisition, Amundi aims to strengthen its leadership in asset management and pursue responsible investment strategies.
The key player in the daptacel market is Sanofi S.A.
North America was the largest region in the daptacel market in 2024. The regions covered in daptacel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the daptacel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Daptacel is a DTaP vaccine that provides protection against diphtheria, tetanus, and pertussis (whooping cough) for children under 7 years old. It is part of the routine immunization schedule for children aged 6 weeks to 6 years, aiming to prevent potentially severe bacterial infections.
The primary technology types used in Daptacel include conjugate, live, recombinant, inactivated, and toxic vaccines. Conjugate vaccines are created by attaching a weak antigen to a stronger antigen, which helps enhance the immune system’s response to the weaker antigen. Daptacel conjugate vaccines are frequently utilized to boost immunity in children against various diseases. The vaccine is indicated for diphtheria, pertussis, and tetanus, and is used for both pediatric and adult age groups. Distribution channels for Daptacel include hospital pharmacies, retail pharmacies, and online pharmacies, with end users primarily consisting of hospitals and clinics.
The daptacel market research report is one of a series of new reports that provides daptacel market statistics, including daptacel industry global market size, regional shares, competitors with a daptacel market share, detailed daptacel market segments, market trends and opportunities, and any further data you may need to thrive in the daptacel industry. This daptacel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The daptacel market consists of sales of single-dose vials and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Daptacel Market Characteristics4. Daptacel Market Trends and Strategies5. Daptacel Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Daptacel Pricing Analysis & Forecasts30. Global Daptacel Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Daptacel Market32. Recent Developments in the Daptacel Market
3. Daptacel Market Biologic Drug Characteristics
6. Global Daptacel Growth Analysis and Strategic Analysis Framework
8. Daptacel Market Segmentation
9. Global Daptacel Epidemiology of Clinical Indications
10. Daptacel Market Regional and Country Analysis
11. Asia-Pacific Daptacel Market
12. China Daptacel Market
13. India Daptacel Market
14. Japan Daptacel Market
15. Australia Daptacel Market
16. South Korea Daptacel Market
17. Western Europe Daptacel Market
18. UK Daptacel Market
19. Germany Daptacel Market
20. France Daptacel Market
21. Eastern Europe Daptacel Market
22. North America Daptacel Market
23. USA Daptacel Market
24. Canada Daptacel Market
25. South America Daptacel Market
26. Middle East Daptacel Market
27. Africa Daptacel Market
28. Daptacel Market Competitive Landscape and Company Profiles
29. Global Daptacel Market Pipeline Analysis
33. Daptacel Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Daptacel Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on daptacel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for daptacel? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The daptacel market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Technology: Conjugate; Live; Recombinant; Inactivated; Toxoid2) by Indication: Diphtheria; Pertussis; Tetanus
3) by Age Group: Pediatric; Adult
4) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) by End-Use: Hospitals; Clinics
Key Companies Mentioned: Sanofi S.a
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi S.A
